Cronos Group Inc.

CRON Healthcare Drug Manufacturers Specialty & Generic

Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024. In the quarter to June 2026, revenue grew 58.4%, EPS grew 190.0%, free cash flow grew 2,279.2% and total debt fell 4.71%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

3.22 0.02 +0.63%
Market cap
$1.2B
P/E
16.1×
Fwd P/E
32.2×
Dividend yield
—
F-score
5/9
Altman Z
12.67
Beneish M
−2.05
Dividend safety
20/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
13.90 251.00 0.00 27.80

+8 more quarters

P/S ratio
5.80 5.97 6.88 8.05
P/FCF ratio
21.01 36.36 0.00 0.00
P/Operating CF
43.26 87.38 85.22 80.02
P/B ratio
0.93 0.85 0.88 0.94
EV/Sales
1.36 0.82 1.21 1.83
EV/EBITDA
19.33 198.71 0.00 0.00
EV/FCF
4.91 5.02 (936.49) (42.17)
Current Ratio
16.18 21.87 19.59 22.45
Net Debt/EBITDA
(73.84) (433.32) 264.61 (271.71)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
7.19% 0.40% (0.38%) 3.60%
Free Cash Flow Yield
4.76% 2.75% (0.02%) (0.54%)
Free Cash Flow per Share
0.06 0.02 0.02 0.02
Book value per Share
2.99 2.96 2.98 2.96
Free Cash Flow
22.23 8.93 9.56 8.72
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates